What is Mosio?
Mosio operates as a specialized provider of text messaging solutions tailored for the rigorous demands of clinical research, including complex clinical trials and behavioral studies. The platform serves as a critical bridge between researchers and participants, utilizing automated messaging, appointment reminders, and SMS-based surveys to drive higher adherence rates. With a proven track record of facilitating over 150 million messages, the company has established itself as an essential partner for universities, hospitals, pharmaceutical firms, and social researchers. By automating manual communication tasks, Mosio enables research teams to focus on high-value data analysis rather than administrative logistics, effectively modernizing the participant experience in a digital-first environment.
How much funding has Mosio raised?
Mosio has raised a total of $96K across 1 funding round:
Debt
$96K
Debt (2021): $96K with participation from PPP
Key Investors in Mosio
PPP
Public-Private Partnership
What's next for Mosio?
With this recent infusion of capital, Mosio is poised to scale its operations and deepen its penetration into the global clinical research market. The strategic focus will likely center on enhancing the platform's automation capabilities and expanding its integration ecosystem to support more complex, multi-site clinical trials. As the demand for remote participant monitoring continues to rise, Mosio's ability to provide secure, scalable, and compliant communication tools will be a key driver of its long-term growth. The company is well-positioned to capitalize on the ongoing digital transformation of healthcare, potentially exploring new therapeutic areas or expanding its footprint in international research markets where participant engagement remains a significant operational challenge.
See full Mosio company page
